Leishmanicidal efficacy of cold atmospheric multiple plasma jet against Leishmania major in a murine model: effects on parasite burden, cytokine profiles, and wound healing Authors: Elham Rezaee, Gholamreza Hatam, Kamiar Zomorodian, Bahador Sarkari, Naghmeh Dastan, Amin Shamsaei, Zahra Gheibi, Hamed Taghvaei Published: 2026 ABSTRACT AbstractCutaneous leishmaniasis (CL) is a neglected tropical disease with limited effective treatments options due to drug toxicity, emerging resistance, and complex therapeutic regimens. The Cold Atmospheric Multiple Plasma Jet (CAMPJ) has recently gained attention as a novel therapeutic modality because it generates reactive oxygen and nitrogen species, with antimicrobial and immunomodulatory activity. This study evaluates the therapeutic efficacy of CAMPJ in a BALB/c mouse model of CL, focusing on its leishmanicidal, wound-healing, and immunomodulatory effects. Female BALB/c mice were inoculated with Leishmania major promastigotes and, after lesion development, assigned to six groups: topical amphotericin B (positive control), CAMPJ (treatment for 5, 10, or 15) minutes, untreated control, and air-treated control. CAMPJ and control treatments were administered twice a week for 21 days, while amphotericin B was applied daily. Lesion progression was monitored weekly using Digitizer software, parasite burden was quantified via Leishman-Donovan Units (LDU), and cytokine levels (IFN-γ and IL-4) were measured by ELISA. CAMPJ treatment produced a significant reduction in lesion size compared with negative controls (p < 0.05), with the 15-minute exposure yielding the greatest improvement. Splenic parasite burden decreased significantly across all CAMPJ-treated groups, again with the 15 min group showing the lowest LDU values. Notably, 15 min CAMPJ exposure promoted a Th1-biased immune response, characterized by elevated IFN-γ and reduced IL-4 contrasting with the Th2 dominant profile observed in untreated controls. These findings indicate that CAMPJ exhibits strong leishmanicidal activity and beneficial immunomodulatory effects, supporting its potential as an alternative or adjunct therapy for CL.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-61618-z.Keywords: Cutaneous leishmaniasis, Cold atmospheric plasma jet, Plasma medicine, Plasma treatment, Wound healingSubject terms: Diseases, Drug discovery, Immunology, Medical research, Microbiology Introduction Leishmaniasis encompasses a group of infectious diseases caused by protozoan parasites belonging to the genus Leishmania1. It is a zoonotic disease prevalent in tropical and subtropical regions and is caused by over 20 distinct Leishmania species2. The disease presents a wide range of clinical manifestations, varying from asymptomatic cases to more severe forms, including pleomorphic cutaneous (CL) and mucocutaneous (MCL) types, as well as potentially fatal visceral leishmaniasis (VL)3,4. According to the World Health Organization (WHO), leishmaniasis is one of the most neglected and uncontrolled re-emerging tropical diseases5–7. Despite significant advancements in the diagnosis and treatment of CL, it continues to pose a major public health challenge in numerous countries worldwide8. Leishmaniasis predominantly affects populations in underdeveloped and developing regions across Africa, Asia, and Latin America. Key risk factors contributing to the disease in these areas include immunodeficiency, malnutrition, rapid urbanization, and substandard living conditions3,9. According to the WHO, the disease was endemic in approximately 98 countries as of 2020. Cases involving both VL and CL were reported in over two-thirds of these nations (71 countries). Additionally, VL was exclusively documented in 8 countries, while CL was exclusively reported in 19 countries3. Globally, an estimated 12 to 15 million individuals are infected with leishmaniasis, with annual reports of 50,000 to 90,000 new cases of VL, 600,000 to 1 million new cases of CL, and approximately 20,000 to 30,000 deaths3,10,11. CL accounts for approximately 70–75% of all leishmaniasis cases6. Leishmaniasis in Iran has a long history, with an annual incidence of approximately 20,000 CL cases. The dominant clinical forms in Iran are zoonotic cutaneous leishmaniasis (ZCL), caused by L. major, and anthroponotic cutaneous leishmaniasis (ACL), caused by L. tropica12,13. ZCL, the rural variant, is prevalent in 15 provinces of Iran, while ACL, the urban variant, affects nearly all urban areas14. For several decades, pentavalent antimonial drugs such as meglumine antimoniate (Glucantime) and sodium stibogluconate (Pentostam) have served as the first-line treatments for CL. Second-line treatments include miltefosine, pentamidine, amphotericin B, and azole derivatives15,16, However, the available therapeutic options face significant limitations, including complex injection regimens, low efficacy, high costs, severe toxicity, therapeutic failure, the potential emergence of drug-resistant parasite strains, and considerable side effects17–19. Given these challenges, the WHO Tropical Disease Research (TDR) Program has underscored the urgent need to develop novel anti-leishmanial therapeutic agents3,20. Plasma therapy has emerged as a promising interdisciplinary approach to medical treatment. Recently, plasma medicine has gained recognition as a field that integrates medical sciences, bioengineering, and plasma physics to achieve therapeutic objectives21. Plasma is one of the four fundamental states of matter, alongside solid, liquid, and gas. It is a quasi-neutral, ionized gas22 which represents a chemically active environment containing a mixture of electrons, reactive oxygen and nitrogen species (ROS/RNS), and uncharged particles such as excited atoms and molecules. Notably, plasma application does not increase the temperature of the material to which it is applied23. In recent years, researchers have shown significant interest in plasma medicine, aiming to develop devices that can effectively deliver reactive species for therapeutic purposes24. Research has demonstrated that cold atmospheric pressure plasma, containing nitrogen (N₂) and oxygen (O₂), can effectively generate reactive oxygen and nitrogen species (RONS) [24]. Over nearly two decades, non-thermal atmospheric plasma (NTAP) technologies have been extensively studied and have found diverse applications in medicine25. These include bacterial elimination26,27, wound healing28, blood coagulation29, and the sterilization of both living and non-living surfaces30. NTAP has also been applied in dentistry, such as teeth whitening, and in cosmetic treatments22. More recently, cold plasma has been a focus of cancer research and has been used to inactivate fungi, such as in the treatment of onychomycosis31. The antimicrobial properties of cold plasma are primarily attributed to the RONS it generates from surrounding gases32. Several limited in vitro studies have investigated the use of cold atmospheric plasma for treating CL. For example, Rezaee et al. and Pournaseh et al. examined the antileishmanial effects of cold plasma on L. major33,34, whereas Adil et al. reported similar findings against L. tropica and L. donovani35. However, to date, no in vivo study has been performed on the effects of cold plasma on CL. Given the crucial role of non-thermal cold atmospheric plasma in generating reactive species and its diverse medical applications—particularly in antimicrobial treatments and wound healing—this study introduces novel approaches that may overcome the limitations of in vitro research and can be considered an innovative investigation. Accordingly, this study aims to evaluate the effects of multi-jet cold atmospheric plasma on CL in BALB/c mice. Materials and methods Materials RPMI-1640 culture medium was purchased from Sinaclon (SNCL). Fetal bovine serum (FBS) was acquired from Sigma (SIG). 100 µg/mL streptomycin from Sigma (SIG) and 100 U/mL of penicillin. The cytokine assay kit was obtained from Kerman Pars Gene (KPG). Liposomal amphotericin B (SinaAmpholeish) was purchased from Exir Nano Sina (ENS). Bradford reagent was obtained from Bio-Rad (BR). Ficoll solution was purchased from Inno-Train (INT). Cold atmospheric multiple plasma jet reactor Structure Designed and built in a laboratory at Shiraz University’s Department of Chemical Engineering, this plasma-jet system comprises a reactor, a high-purity air capsule (21% oxygen, 79% nitrogen), an air-flow controller, an AC power supply, an oscilloscope, and voltage and current probes. The reactor produces cold atmospheric plasma jets via a central steel electrode connected to the power supply and surrounded by 14 quartz tubes (2 mm outer diameter). A copper sheet envelops these tubes to serve as the external electrode; it is held in place by a transparent, flexible sleeve that also forms the gas-entry chamber within the quartz microtubes (Fig. 1)36,37. Schematic of a multiple-jet plasma reactor design. A 1-pF capacitor installed in series with the outer-electrode line monitored the charge (Q). The instantaneous voltage Vm(t) was measured with a Tektronix TPP0200 passive probe, and the applied voltage (V) with a Tektronix P6015A high-voltage probe (1000:1). All signals were recorded on a Tektronix TDS 1012B-SC oscilloscope at a 1.0 GS/s sampling rate and 100 MHz bandwidth. Treatment parameters for the CAMPJ exposure were set to a gas flow rate of 500 mL/min, an applied voltage of 8.6 kV, and a nozzle-to-lesion distance of 1 cm, with irradiation times of 5, 10, and 15 min. To determine the optimal plasma processing conditions for in vivo studies, we first evaluated the effects of various plasma parameters including voltage, gas flow rate, nozzle to sample distance, exposure time, and parasite concentration on L. major promastigotes under in vitro conditions. The parasite containing solution was subjected to plasma treatment, and the condition that yielded the highest parasite inactivation was selected as the operational setting for the in vivo experiments. In vivo model and experimental inoculation of BALB/c mice Female BALB/c mice (4–6 weeks old), weighing 15–20 g at the beginning of the experiment, were obtained from the Royan Institute (Karaj, Iran) and housed at 23 ± 1 °C, 55% relative humidity, on a 12 h light/dark cycle with free access to food and water. Each mouse was inoculated subcutaneously at the tail base with 0.1 ml of PBS containing 2 × 10⁶ stationary-phase promastigotes of L. major (strain MRHO/IR/76/ER). Twenty-eight days post-inoculation, once nodules and lesions were evident, were randomly assigned to six groups of five animals each. Treatment and wound-size assessment Thirty mice infected with the parasite were randomly divided into six groups (n = 5 per group). Group 1 received cold plasma treatment for 5 min (P‑5), Group 2 for 10 min (P‑10), and Group 3 for 15 min (P‑15), with each treatment administered twice weekly for a period of 21 days. Plasma exposure was delivered in a non‑contact manner at a fixed working distance of 1 cm, using the CAMPJ device operated at 8.6 kV and a gas flow rate of 500 mL/min. Group 4 served as the negative control and received no treatment. Group 5 (device control; 500 A) was exposed to the same airflow (500 mL/min) and treatment schedule but without plasma activation, ensuring that any observed effects could be attributed to plasma‑generated reactive species rather than to gas flow alone. Group 6 (positive control) was treated topically with liposomal amphotericin B gel containing 4 mg/ml amphotericin B once daily for four weeks. The details of the experimental and control groups are presented in Table 1. The size of the lesions was assessed using Digitizer software by taking weekly photographs of each lesion alongside a ruler for scale. No general anesthesia was required during plasma treatment, as the procedure was non-invasive, brief, and well-tolerated by the animals. Mice were gently restrained manually during treatment to avoid stress and movement. One week after completion of the treatment period, animals were humanely euthanized using a chemical method, specifically carbon dioxide (CO₂) inhalation, administered in a dedicated euthanasia chamber with a gradual fill rate (20–30% chamber volume per minute), in accordance with AVMA Guidelines for the Euthanasia of Animals. Table 1Description of treatment groups.GroupsTreatmentDosage and treatment durationG1 (P-5)CAMPJ exposure 5 minVoltage: 8.6 kVGas flow rate: 500 mL/minDistance of 1 cmTwice a week for 21 daysG1 (P-10)CAMPJ exposure 10 minVoltage: 8.6 kVGas flow rate: 500 mL/minDistance of 1 cmTwice a week for 21 daysG1 (P-15)CAMPJ exposure 15 minVoltage: 8.6 kVGas flow rate: 500 mL/minDistance of 1 cmTwice a week for 21 daysG4 (Control -)–Without treatmentG5 (Device control)Air flow only500 ml/minTwice a week for 21 daysG6 (Control +)Liposomal amphotericin B4 mg/ml topical gel daily for 28 days Description of treatment groups. Voltage: 8.6 kV Gas flow rate: 500 mL/min Distance of 1 cm Twice a week for 21 days Voltage: 8.6 kV Gas flow rate: 500 mL/min Distance of 1 cm Twice a week for 21 days Voltage: 8.6 kV Gas flow rate: 500 mL/min Distance of 1 cm Twice a week for 21 days 500 ml/min Twice a week for 21 days Evaluation of parasite burden by LDU method Parasite burden was assessed by counting amastigotes in Giemsa-stained impression smears prepared from spleen tissue. Results were expressed as Leishman–Donovan units (LDU), with the LDU index calculated using the following formula38: Parasite culture The L. major standard strain (MRHO/IR/75/ER) was initially cultured in Novy-MacNeal-Nicolle (NNN) medium and subsequently maintained through sub-passing in RPMI 1640 supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin at 25 °C. Preparation of soluble Leishmania antigen (SLA) Soluble Leishmania antigen (SLA) was prepared from promastigotes harvested in the late stationary phase (4–6 days post cultivation). Thirty milliliters of culture were transferred into a 50 mL centrifuge tube and pelleted by centrifugation at 2800 × g for 15 min at 4 °C. The pellets were washed three times with phosphate-buffered saline (PBS) and subjected to three rapid freeze–thaw cycles to ensure complete cell lysis. The lysate was then centrifuged at 5000 × g for 20 min at 4 °C, and the resulting supernatant was collected and stored at − 80 °C until use38. ELISA for determination of cytokine levels Mononuclear cells were isolated from mouse spleens by density gradient centrifugation using Ficoll-Lymphodex (Inno-train, Kronberg, Germany). The cells were washed and resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). For stimulation assays, 1 × 10^6 cells per well were plated in 48-well flat-bottom plates and incubated with 3 µg/mL soluble (SLA). Negative control wells received medium alone, whereas positive control wells were stimulated with 10 µg/mL concanavalin A. After 72 h, supernatants were collected and stored at − 20 °C, and cell pellets were stored at − 70 °C until further analysis. Interferon-γ (IFN-γ) and interleukin-4 (IL-4) concentrations in the supernatants were determined in triplicate by sandwich ELISA using commercial kits (Karmania Pars Gene, Iran) in accordance with the manufacturer’s instructions. Thermal characterization and infrared thermography To investigate the thermal behavior of the plasma reactor and its potential effects on animal body temperature, infrared (IR) thermography was employed as a non‑invasive diagnostic tool. The surface temperature distribution of the reactor and the outlet gas flow during plasma discharge were monitored in real time using a Testo thermal imager. The captured thermal data were subsequently processed and analyzed using the manufacturer’s software (version 5.2). Statistical analysis Statistical analyses were performed using SPSS (version 27), and graphs were generated with GraphPad Prism. Differences among the six experimental groups were analyzed using one-way ANOVA followed by Tukey’s post-hoc test, which compared each group against all other groups as well as individually against the infected untreated control. Lesion size progression over time was assessed using repeated-measures ANOVA. A p-value of less than 0.05 was considered statistically significant. All in vivo data were based on triplicate measurements and are presented as the mean ± standard deviation (SD). Result Temperature effect assessment Before commencing animal experiments, we first verified the potential influence of device temperature and plasma processing on tissue heating. The temperature distribution was measured both on the reactor and on the target tissue placed at a distance of 1 cm from the reactor (Fig. 2). The results showed that the maximum reactor temperature reached 79.8 °C, 90.5 °C, and 95.4 °C after 5, 10, and 15 min of plasma processing, respectively. In contrast, the temperature of the target tissue at the 1-cm distance remained approximately 39 °C, with no significant change over time. Temperature profile of the plasma reactor and target as a function of treatment time. Lesion size measurement After the treatment was completed, the lesion size was measured and recorded weekly before, during, and after the intervention. There were no statistically significant differences in the sizes of the lesions among the various groups (P > 0.05) before the initiation of treatment (Fig. 3 and Table S1). After treatment, the plasma-treated groups (5, 10, 15 min) exhibited smaller wound sizes than the negative and device control groups (P < 0.05). The lesion size in the cold atmospheric plasma-treated groups was not significantly reduced compared to the positive control group (P > 0.05). Although no statistically significant differences were observed among the plasma treatment groups (P > 0.05), a dose-dependent effect on lesion control was evident. Exposure durations of 5 min and 10 min led to increases in lesion size of 45.6% and 44.8%, respectively, both of which remained significantly lower than that of the untreated negative control group. Notably, the 15‑min plasma exposure proved most effective, maintaining lesion size at an almost constant level throughout the study period. The device control group (airflow rate 500 ml/min) and the untreated negative control group showed the largest mean lesion size (P > 0.05). Lesion progression in BALB/c mice infected with L. major and treated as follows: Treatment groups: cold atmospheric plasma exposure for 5, 10, or 15 min (p-5 min, p-10 min, p-15 min), topical SinaAmpholeish gel (positive control); air flow at 500 ml/min (500 A); untreated mice (negative control). Data are expressed as mean lesion area ± SD (n = 5). Assessment of CAMPJ treatment efficacy based on parasite load One week after the end of treatment, the parasite load in the spleens of BALB/c mice was measured using the LDU method (Fig. 4 and Table S2). The parasite load in the plasma and positive control treatment groups was significantly reduced compared with the negative control and device control groups (P < 0.0001). Plasma exposure for 10 and 15 min showed a statistically significant difference compared with the positive control group (P < 0.001). The 15 min plasma treatment group showed the greatest reduction in parasite load compared with the other two treatment groups (5 and 10 min) (P < 0.01). No significant difference was observed between the 5 min plasma treatment group and the positive control group (P > 0.05). Splenic parasite burden in BALB/c mice as quantified by LDU method. Parasite loads are expressed as LDU values for each experimental group (n = 5). Treatment groups: cold atmospheric plasma exposure for 5, 10, or 15 min (p-5 min, p-10 min, p-15 min), topical SinaAmpholeish gel (positive control); air flow at 500 ml/min (500 A); untreated mice (negative control). Note: ns indicates no significant difference, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Assessment of cytokine levels The concentrations of IFN-γ and IL-4 were quantified using ELISA to evaluate the Th1/Th2 immune responses (Fig. 5 and Table S3). A significant increase in IFN-γ levels was observed in all plasma-treated groups (5, 10, and 15 min) compared with the negative control and the 500 A device-control group (P < 0.0001). Among the treatment groups, the 15-min plasma exposure produced the highest IFN-γ level (P < 0.01). When compared with the positive control, both the 10- and 15-min plasma-treated groups showed significantly higher IFN-γ levels, whereas the 5-min group did not differ significantly (P < 0.05). In contrast, IL-4 levels were markedly reduced in all plasma-treated groups relative to the negative control and the 500 A group (P < 0.0001). The lowest IL-4 concentration was detected in the 15-min plasma-treated group (P < 0.01). Comparison with the positive control indicated that the 10- and 15-min treatment groups exhibited significantly lower IL-4 levels, while the 5-min group did not differ significantly (P < 0.05). Cytokine production by spleen cells from L. major–infected BALB/c mice following treatment. Beginning on day 30 post-infection. Spleen cells were harvested, cultured with Leishmania antigen, and supernatants assayed by ELISA for interferon-γ (IFN-γ; panel A) and interleukin-4 (IL-4; panel B). Treatment groups: cold atmospheric plasma exposure for 5, 10, or 15 min (p-5 min, p-10 min, p-15 min), topical SinaAmpholeish gel (positive control); air flow at 500 ml/min (500 A); untreated mice (negative control). Data are presented as mean cytokine concentration ± SD (n = 5). Note: ns indicates no significant difference, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Discussion CL is a neglected tropical disease for which the current main therapies, pentavalent antimonials and amphotericin B, are limited by high cost, prolonged treatment courses, adverse side effects, and increasing drug resistance, leading to frequent relapse39. These challenges underscore the need for safe and effective alternative therapies. WHO also emphasizes the urgent need for alternative treatments for CL23,40. In recent years, cold atmospheric plasma (CAP), an emerging bioengineered technology, has gained attention as a promising therapeutic option. CAP is a partially ionized, near-room-temperature gas containing reactive oxygen and nitrogen species, charged particles, and ultraviolet photons, enabling potent antimicrobial and anti-parasitic activity while sparing healthy tissues. Cold atmospheric plasma therapy generates reactive oxygen species (ROS) and reactive nitrogen species (RNS), which exert potent cytotoxic effects on microbes—including protozoan parasites while avoiding thermal damage to surrounding tissues23,24,41. In this study, a CAMPJ device employing high-purity air as the feed gas was developed and shown to efficiently produce these reactive species. These reactive species play a central role in the anti-parasitic activity of CAP. ROS and RNS can disrupt cellular homeostasis by inducing oxidative stress, damaging membrane lipids, proteins, and nucleic acids, ultimately leading to apoptosis or necrosis of the parasite42,43. In addition, CAP-generated reactive species can modulate the host immune response by promoting local inflammatory mediators, enhancing macrophage phagocytic activity, and stimulating signaling pathways involved in wound healing and tissue remodeling44. Through this combination of direct cytotoxic and indirect immunomodulatory effects, CAP provides a targeted, non-thermal therapeutic strategy against Leishmania and other pathogenic microorganisms45,46. In this study, CAMPJ treatment demonstrated significant therapeutic efficacy against L. major-induced CL in BALB/c mice, as evidenced by inhibited lesion growth, reduced splenic parasite burden, and polarization toward a Th1-biased immune response. All CAMPJ-treated cohorts (5, 10, and 15 min) and the positive control group exhibited a statistically significant reduction in lesion size versus the untreated control (p < 0.05) (Fig. 3), underscoring the combined wound-healing and leishmanicidal activities of cold plasma. The treatment’s efficacy was clearly exposure-dependent. Notably, the 15-min exposure group displayed the most pronounced therapeutic effect, achieving near-complete suppression of lesion growth and effectively stabilizing wound size throughout the study period. The final lesion size in this group was comparable to, and indeed slightly smaller than, that observed in the positive control group47. Given the limited number of studies investigating the effects of cold plasma on leishmaniasis, the findings of the present study were compared with those reported in other infectious disease models. These results are consistent with previous studies on non-thermal plasma in infectious disease models. For instance, Ermolaeva et al. (2011) reported that cold plasma treatment in a murine Pseudomonas aeruginosa infection model reduced wound size by enhancing tissue regeneration and lowering bacterial load through the generation of ROS and NO48. Similarly, in another study using a murine third-degree burn wound model, treatment with cold atmospheric plasma significantly reduced wound size by activating eNOS and enhancing NO production in endothelial cells49. These observations suggest that the reactive oxygen and nitrogen species generated by CAMPJ may promote tissue regeneration and, importantly, attenuate inflammation by downregulating pro-inflammatory cytokines and limiting excessive immune cell infiltration at the lesion site24. Another study in a mouse skin wound model infected with P. aeruginosa demonstrated that treatment with plasma-activated water (PAW) significantly accelerated wound healing, without causing damage to host tissue or organs48,50. Furthermore, Isbary et al. (2010) reported that daily multi-week cold plasma treatment in patients with chronic wounds led to partial wound healing46. In the next step, the parasite load was examined. The marked reduction in splenic parasite burden, most pronounced in the 15-min plasma group, underscores the leishmanicidal efficacy of CAMPJ. This response was exposure-duration–dependent: the 10-min treatment yielded an intermediate decrease in parasite load, while the 5-min exposure achieved reductions comparable to those observed with the positive control group (Fig. 4). These results mirror previous reports on cold plasma’s antimicrobial action; for instance, Daeschlein et al. (2012) demonstrated that low-temperature plasma reduced Staphylococcus aureus and Escherichia coli counts via ROS-mediated oxidative stress and membrane disruption51. Similarly, animal studies have shown that plasma products, including plasma-activated water (PAW), can significantly reduce microbial load through the sustained presence of reactive oxygen and nitrogen species (ROS/RNS), while avoiding systemic toxicity50. The comparable performance of the 5-minute CAMPJ treatment and positive control group suggests that shorter plasma exposure may still be clinically effective, offering potential advantages over long-course therapies such as amphotericin B18. However, complete parasite clearance was not achieved, consistent with the chronic and resilient nature of CL. The cytokine profile analysis demonstrated a pronounced shift toward a Th1-biased response in plasma-treated groups. Notably, the 15-min treatment elicited the highest IFN-γ levels alongside the lowest IL-4 levels. This Th1 polarization is critical for controlling Leishmania infections, as IFN-γ activates macrophages to eliminate intracellular amastigotes, whereas IL-4 promotes a Th2 response that worsens disease progression4. In contrast, the untreated and air-treated (500 A) groups maintained a Th2-biased profile, reflecting BALB/c mice’s known susceptibility to L. major10. The immunogenic effects of CAMPJ are novel, showing that plasma directly targets the parasite while also stimulating the host immune system. These results are consistent with the study by Bekeschus et al. (2018), who showed that plasma increased IFN-γ production in human immune cells by activating ROS and NO-dependent pro-inflammatory pathways, stimulating leukocytes, and enhancing immune defense52. Likewise, Arndt et al. (2013) demonstrated that plasma-induced ROS modulates immune responses during wound healing, cultivating a pro-inflammatory milieu conducive to pathogen clearance53. The pronounced Th1 polarization observed with CAMPJ may be related to the immunomodulatory effects of plasma-generated reactive species, which can influence inflammatory pathways and macrophage activation. However, the specific molecular mechanisms underlying this shift were not investigated in the present study and require further targeted analysis54,55. These results demonstrate that CAMPJ exposure, particularly with a 15-min treatment, holds promise as a noninvasive therapy for CL. By potentially circumventing the toxicity, emerging resistance, and complex dosing regimens associated with pentavalent antimonials and amphotericin B, CAMPJ could offer a safer, more accessible alternative or adjunct to existing drugs. Moreover, these findings align with a growing body of research advocating non-pharmacological, low-toxicity approaches for CL that either potentiate host immune responses or leverage innovative delivery platforms for enhanced therapeutic outcomes3,8,23. Despite the promising outcomes, this study has several limitations. The incomplete lesion healing observed may relate to the chronic nature of CL, parasite persistence, and the relatively short treatment duration. Similar to topical paromomycin, which often requires prolonged or repeated treatment for full recovery20. In fact, Ben Salah et al. (2013) demonstrated that daily paromomycin applications for 20–30 days were necessary to achieve significant healing, suggesting that more frequent or prolonged CAMPJ treatments could improve outcomes56. Another limitation is the exclusive use of BALB/c mice, which exhibit a Th2‑biased immune response; this may restrict the generalizability of our immunological findings to other mouse strains and to humans. 10. In contrast, Scott et al. (2016) reported that Th1-biased C57BL/6 mice mount stronger IFN-γ responses to L. major, indicating that CAMPJ’s immunomodulatory effects might differ across host backgrounds57 Furthermore, the study did not discriminate between parasiticidal ROS/RNS levels and potentially harmful oxidative overproduction, nor did it measure tissue-level oxidative stress or cytotoxicity. The selected 5, 10, and 15-minute exposure times were based on preliminary optimization, but the absence of in-tissue RONS measurements, oxidative biomarkers, and histopathology constitutes a methodological limitation requiring further investigation. Additionally, Th1/Th2 polarization was inferred solely from IFN-γ and IL-4 ELISA data, without flow-cytometric characterization of T-cell subsets, which should be incorporated in future studies. Future investigations should incorporate alternative animal models (e.g., C57BL/6 mice) and human macrophage or keratinocyte systems to better define CAMPJ’s immunological and therapeutic profile. Further refinement of CAMPJ operational parameters may enhance efficacy while minimizing oxidative tissue stress; as noted by Weltmann et al. (2016), matching plasma discharge characteristics to target tissues is essential for avoiding excessive oxidative damage58. Combination approaches with established antileishmanial agents including miltefosine or amphotericin B are also promising, as combination therapy has yielded superior outcomes in CL59. Finally, clinical translation will require advances in user-friendly, portable plasma devices, such as those described by Fridman et al. (2008), to enable broader implementation in endemic settings42. Conclusion In this murine model, topical CAMPJ treatment reduced lesion size, lowered parasite burden, and induced cytokine changes consistent with a Th1-skewed response compared with untreated controls. Collectively, these findings demonstrate that CAMPJ exerts measurable therapeutic activity against L. major under the experimental conditions applied. However, lesion healing remained incomplete, and this study did not evaluate long-term outcomes, safety parameters, or potential relapse, making the current results preliminary. Further research is needed to optimize dosing, assess combination strategies with established antileishmanial drugs, and replicate these findings in additional animal models. Overall, CAMPJ represents a promising experimental approach with the potential to be developed as a future therapeutic option for leishmaniasis, pending further confirmatory studies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The results described here was a part of the Ph.D. thesis of Elham Rezaee. Author contributions B.S, H.T, GH.H and K.Z designed experiments. E.R, N.D and A.SH performed experiments. E.R, Z.GH, B.S, H.T and N.D analyzed data and interpreted experiments. E.R, B.S and H.T wrote and/or edited the manuscript. All authors read and approved the final manuscript. Funding The study was financially supported by a grant of the Office of Vice-Chancellor for Research of Shiraz University of Medical Sciences (SUMS to BS) (Grant No. 27882). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data availability All data supporting the findings of this study are available within the paper. Declarations Competing interests The authors declare no competing interests. Ethics declarations All animal experiments are reported in accordance with the ARRIVE guidelines. Experimental design, sample size determination, randomization, blinding, outcome measures, and statistical methods are described following ARRIVE recommendations. Animal procedures were approved by the Institutional Animal Care and Use Committee of Shiraz University of Medical Sciences, approval number: IR.SUMS.REC.1402.504) and were performed in accordance with institutional and national guidelines for the care and use of laboratory animals. Consent for publication All authors consent for the final manuscript for publication. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data supporting the findings of this study are available within the paper.